Completed PHASE3 INTERVENTIONAL NCT00128739

Treatment of Gastro-Intestinal and/or Hepatic Graft Versus Host Disease With Budesonide in Patients Following Peripheral Blood Stem Cell Transplantation

A Phase 3 Study to Evaluate the Place of Budesonide in the Treatment of GVHD

Sponsor: Dr. Falk Pharma GmbH

Interventions Budesonide

Updated 5 times since 2017 Last updated: Aug 26, 2005 Started: Jan 31, 2001 Completion: Aug 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Graft Vs Host Disease and is currently completed. Dr. Falk Pharma GmbH leads this study, which shows 5 recorded versions since 2001 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jan 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dr. Falk Pharma GmbH
Rafa Laboratories

Data source: Rafa Laboratories

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Jerusalem, Israel